Jeremy Sturgess-Smith, Finance Director of Ananda Developments Plc (AQSE:ANA), presented an overview of the company, which has been quoted since 2018. The company focuses on CBD as a treatment for multimorbidity, noting its potential effectiveness due to its interaction with multiple receptors in the body. Ananda Developments is particularly interested in complex conditions like inflammation and pain, areas highlighted by NICE for further research.
Sturgess-Smith detailed their two upcoming Phase II clinical trials in partnership with Edinburgh University. The first trial targets chemotherapy-induced peripheral neuropathy, aiming to address the poor current treatment options for the 160,000 patients affected annually. The second trial will focus on endometriosis, a painful condition affecting 10% of women globally. This trial, funded with £300,000 from the Chief Scientist Office in Scotland, aims to assess patient uptake and retention.
Ananda Developments benefits from having influential board members, including Charles Morgan, Melissa Sturgess, Clive Page, and advisors like Professor Trevor Jones and Professor Cherry Wainwright, who bring extensive expertise in biotech and pharmacology.
The company is also focusing on non-dilutive grant funding and ensuring regulatory compliance to enhance market access, particularly through the NHS. Despite recent share price challenges, Ananda remains committed to its clinical trial pathways and improving treatments for conditions like endometriosis.
